title: Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.
abstract: OBJECTIVE
  The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy.
  
  
  METHODS
  We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer prior to additional platinum therapy. All patients were treated between July 1, 1997, and June 30, 2001. Platinum resistance was defined as less than a partial response to platinum therapy or progression within 6 months of the last platinum therapy.
  
  
  RESULTS
  Overall, 7 of 30 patients experienced an objective response to platinum therapy (partial response, 23%; complete response, 0%) based on CT scan (2/21) and/or CA-125 (5/9) criteria. The median time to progression for the group was 17 weeks (range, 4-59 weeks). Several predictive factors were identified. The interval since the last platinum treatment did not appear to be predictive in this group. Only 1 of 16 patients who did not have an objective response to the most recent platinum-based therapy responded to platinum rechallenge. Similarly, no patient who received more than three intervening nonplatinum treatments responded to additional platinum therapy (0/10).
  
  
  CONCLUSIONS
  Our small retrospective series suggest that the platinum-resistant category is heterogenous and includes patients who may respond to retreatment with platinum-based agents. This group includes the patients with prior platinum responses and early progression. However, patients without an objective response to the last prior platinum therapy or more than three intervening treatments are unlikely to respond to subsequent platinum therapy.
authors.affiliation: Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. spriggsd@mskcc.org
authors.forename: Mario M
authors.initials: MM
authors.lastname: Leitao
authors.forename: Amanda
authors.initials: A
authors.lastname: Hummer
authors.forename: Don S
authors.initials: DS
authors.lastname: Dizon
authors.forename: Carol
authors.initials: C
authors.lastname: Aghajanian
authors.forename: Martee
authors.initials: M
authors.lastname: Hensley
authors.forename: Paul
authors.initials: P
authors.lastname: Sabbatini
authors.forename: Ennapadam
authors.initials: E
authors.lastname: Venkatraman
authors.forename: David R
authors.initials: DR
authors.lastname: Spriggs
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000077146:Irinotecan; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin; D002166:Camptothecin